Posted by Michael Wonder on 12 Mar 2018
Regeneron and Sanofi announce plans to make Praluent (alirocumab) more accessible and affordable for patients with the greatest health risk and unmet need
10 March 2018 - For payers willing to reduce access barriers for high-risk patients, companies will offer net price within a cost-effective range, leveraging a new ICER analysis.
To help ensure more affordable and timely access to patients most in need, Regeneron Pharmaceuticals and Sanofi will offer payers that agree to reduce alignment with a new value assessment for high-risk patients from ICER.
The companies will take a precision medicine approach to address the burden of cardiovascular disease (CV), focusing efforts on high-risk patients most vulnerable to future CV events, such as those who have suffered a previous coronary event and are unable to reduce their LDL cholesterol (LDL-C) below 100 mg/dL despite maximally-tolerated statin therapy.
